• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Novopharm fined $1.25 million for contempt of court

Article

Pharmaceutical Representative

In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.

In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.

Novopharm was fined for failure to comply with a court order to disclose documents pertaining to the drug Lovastatin, for secretly resuming research on the product and for making submissions to the government using illegally retained documents.

According to a statement issued by Associate Chief Justice Oliphant, Novopharm's actions were motivated by a desire to bring Lovastatin to market before rival products, such as those produced by pharmaceutical company Apotex Inc. "The contemptuous conduct here was, I believe…fueled by what must be one of the most bitter business rivalries I have ever witnessed," Oliphant said.

In the past, Novopharm was held liable for misappropriation of technology from a fermentation facility in Winnipeg owned by Apotex.

As a result, Novopharm cannot use the technology and was ordered to pay damages to Apotex in the amount of $6.5 million.

In addition to the most recent fine of $1.25 million, the court also ordered Novopharm to pay all of the legal costs that Apotex incurred as a result of the contempt proceedings. PR

Recent Videos
Related Content